InnoCan Pharma Corporation (FRA:IP40)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.14M -81.6% |
| Revenue (ttm) | 21.93M -17.0% |
| Net Income | -1.31M |
| EPS | -0.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.620 |
| Previous Close | 1.615 |
| Day's Range | 1.620 - 1.635 |
| 52-Week Range | 1.545 - 13.200 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About InnoCan Pharma
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vag... [Read more]
Financial Performance
In 2025, InnoCan Pharma's revenue was $26.61 million, a decrease of -9.60% compared to the previous year's $29.44 million. Losses were -$1.12 million, -38.71% less than in 2024.
Financial numbers in USD Financial StatementsNews
InnoCan Pharma Registration statement: Q1 2026
InnoCan Pharma filed a registration statement on May 27, 2026, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q1 2026
InnoCan Pharma filed a registration statement on May 27, 2026, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q1 2026
InnoCan Pharma released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.
InnoCan Pharma Earnings release: Q4 2025
InnoCan Pharma released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q4 2025
InnoCan Pharma filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q4 2025
InnoCan Pharma filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusi...
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biot...
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
HERZLIYA, Israel and CALGARY, AB, Feb. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biote...
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focus...
InnoCan Pharma Registration statement: Q3 2025
InnoCan Pharma filed a registration statement on November 27, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q3 2025
InnoCan Pharma filed a registration statement on November 27, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q3 2025
InnoCan Pharma released its Q3 2025 earnings on November 27, 2025, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q2 2025
InnoCan Pharma filed a registration statement on August 27, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q2 2025
InnoCan Pharma filed a registration statement on August 27, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q2 2025
InnoCan Pharma released its Q2 2025 earnings on August 27, 2025, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q1 2025
InnoCan Pharma filed a registration statement on May 28, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q1 2025
InnoCan Pharma filed a registration statement on May 28, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q1 2025
InnoCan Pharma released its Q1 2025 earnings on May 28, 2025, summarizing the period's financial results.
InnoCan Pharma Earnings release: Q4 2024
InnoCan Pharma released its Q4 2024 earnings on March 31, 2025, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q4 2024
InnoCan Pharma filed a registration statement on March 31, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q4 2024
InnoCan Pharma filed a registration statement on March 31, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q3 2024
InnoCan Pharma filed a registration statement on November 20, 2024, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q3 2024
InnoCan Pharma released its Q3 2024 earnings on November 20, 2024, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q3 2024
InnoCan Pharma filed a registration statement on November 20, 2024, providing details about a securities offering with the SEC.